PTC Therapeutics ( (PTCT) ) has released its Q4 earnings. Here is a breakdown of the information PTC Therapeutics presented to its investors.
PTC Therapeutics, Inc. is a global biopharmaceutical company focused on developing and commercializing medicines for rare disorders, leveraging its scientific expertise and global infrastructure to maximize value for patients and stakeholders.
In its latest earnings report, PTC Therapeutics announced a full-year 2024 revenue of $807 million, surpassing its guidance, and highlighted the achievement of all clinical and regulatory milestones, including four NDA submissions. The company also closed a license and collaboration agreement with Novartis for its Huntington’s disease program in early 2025.
Key financial metrics showed a fourth-quarter revenue of $213 million, with the DMD franchise contributing $144 million. The company reported a net loss of $65.9 million for the fourth quarter, an improvement compared to the previous year’s loss. PTC also maintained a strong cash position with over $2 billion as of January 2025, supporting its commercial and R&D activities.
Strategically, PTC achieved significant regulatory milestones, including FDA approval for Kebilidi and priority reviews for other treatments. The collaboration with Novartis and ongoing trials, such as the PIVOT-HD Phase 2 study, are expected to further bolster its pipeline.
Looking ahead, PTC anticipates 2025 revenues between $600 million and $800 million, with continued investment in R&D and SG&A activities. The company’s management remains optimistic about sustaining its growth trajectory and advancing its pipeline of transformative medicines.